Reports suggest that IDH1/2 mutations [106], inhibition of glutaminolysis [107], and mitochondrial cristae remodeling [108], and OXPHOS uncoupling [62] increase the anti-cancer efficacy of ABT-199. This evidence concerns the gene IDH1 and cancer.